NFKB1 and COVID-19: Thus, the pharmacological inactivation of the NF-κB signaling pathway can represent a potential therapeutic target to treat severe COVID-19 (Kircheis et al., 2020; Hariharan et al., 2021; Kandasamy, 2021).